With an ambitious development strategy, focused on the needs of its sponsors, and the strengthening of synergies within the company and with its partners, Cynbiose unveils today its new brand identity and logo!
Cynbiose’s new logo reflects the shift the company is taking in the coming years with a new building dedicated to preclinical research and unique infrastructure in Europe. The company is also strengthening its positioning in infectious and respiratory diseases and the evaluation of advanced therapy medicinal products (ATMPs) including gene therapies (GTMPs).
The logo embodies the company’s strategic positioning as a key player in the preclinical services sector, the dynamism of its teams and development, and the trust placed in it by its clients and partners.
The new brand identity reflects Cynbiose’s core values of expertise, innovation, reliability, flexibility and collaboration.
The new identity also reflects the commitment of Cynbiose teams to its partners and sponsors to contribute to the successful development of tomorrow’s medicines.
Read the press release and our CEO’s statement.
French version is available here.
